Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
QingQing Cai, MD. PhD.
CONTACT
Yi Xia, MD. PhD.
CONTACT
Lead
Sun Yat-sen University
With
The purpose of this phase II clinical trial is to evaluate the efficacy and safety of selinexor in combination with R-CHOP for untreated TP53-mutated DLBCL patients. The induction phase consisted of 8 cycles of selinexor in combination with R-CHOP. After 8 cycles of induction therapy, if the response is assessed as complete remission (CR), maintenance therapy with selinexor will be conducted. The primary endpoint is complete response rate.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
